Home / Market News / $HRTX
benzinga Corporate Catalyst Impact 95/100 ● negative

Heron Therapeutics Q2 EPS $(0.03) Misses $(0.01) Estimate, Sales $37.666M Miss $42.200M Estimate

Aug 10, 2026, 12:01 PM UTC · Primary ticker $HRTX

Heron Therapeutics reported a significant miss on both Q2 earnings per share and sales compared to analyst estimates. This indicates weaker-than-expected financial performance for the quarter, which is typically a strong negative signal for investors.

Heron Therapeutics (HRTX) reported a Q2 EPS of $(0.03), missing the analyst consensus of $(0.01) by an 'Infinity percent' (indicating a larger loss than anticipated), and sales of $37.666 million, missing the $42.200 million estimate by 10.74%. While sales did show a slight increase year-over-year, the larger-than-expected loss and significant sales miss are strong negative indicators. This financial underperformance suggests potential challenges in product adoption, market competition, or operational efficiency. For traders, this news likely implies short-term downward pressure on HRTX stock as investors react to the disappointing results, potentially leading to a re-evaluation of the company's growth prospects and valuation.

$HRTX negative Missed Q2 EPS and sales estimates
Source: benzinga
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.